Evidence map›Paper›PMID 33614519›Full record

ArticleFrontiers in oncology2021

Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity.

Federico La Manna, Marta De Menna, Nikhil Patel, Sofia Karkampouna, Maria Rosaria De Filippo, Irena Klima, Peter Kloen, Lijkele Beimers, George N Thalmann, Rob C M Pelger and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Federico La MannaDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.
Marta De MennaDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.
Nikhil PatelDepartment of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, NJ, United States.
Sofia KarkampounaDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.
Maria Rosaria De FilippoDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.
Irena KlimaDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.
Peter KloenDepartment of Orthopedic Trauma Surgery, Academic Medical Center, Amsterdam, Netherlands.
Lijkele BeimersDepartment of Orthopedic Surgery, MC Slotervaart, Amsterdam, Netherlands.
George N ThalmannDepartment of Urology, Inselspital, Bern University Hospital, Bern, Switzerland.
Rob C M PelgerDepartment of Urology, Leiden University Medical Center, Leiden, Netherlands.
Estela JacintoDepartment of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, NJ, United States.
Marianna Kruithof-de JulioDepartment for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article .].

Indexed as

ALDHbone metastasisdisulfirammTORPDXprostate cancer

Identifiers

PMID33614519
PMCPMC7887433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.